Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study

VJ Sallinen, TTY Le Large, E Tieftrunk, S Galeev, Z Kovalenko, SP Haugvik, A Antila, O Franklin, E Martinez-Moneo, SM Robinson, F Panzuto, N Regenet, F Muffatti, S Partelli, D Wiese, P Ruszniewski, B Dousset, B Edwin, DK Bartsch, A SauvanetM Falconi, GO Ceyhan, S Gaujoux, on the behalf of the Pancreas 2000 research group

Research output: Contribution to journalArticle

Abstract

Background: Malignant potential of small (≤20 mm) nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to predict and management remain controversial. The aim of this study was to assess the prognosis of sporadic nonmetastatic sNF-PNETs. Methods: Patients were identified from databases of 16 centers. Outcomes and risk factors for recurrence were identified by uni- and multivariate analyses. Results: sNF-PNET was resected in 210 patients, and 66% (n = 138) were asymptomatic. Median age was 60 years, median tumor size was 15 mm, parenchyma-sparing surgery was performed in 42%. Postoperative mortality was 0.5% (n = 1), severe morbidity rate was 14.3% (n = 30), and 14 of 132 patients (10.6%) with harvested lymph nodes had metastatic lymph nodes. Tumor size, presence of biliary or pancreatic duct dilatation, and WHO grade 2-3 were independently associated with recurrence. Patients with tumors sized ≤10 mm were disease free at last follow-up. The 1-, 3- and 5-year disease-free survival rates for patients with tumors sized 11-20 mm on preoperative imaging were 95.1%, 91.0%, and 87.3%, respectively. Conclusions: In sNF-PNETs, the presence of biliary or pancreatic duct dilatation or WHO grade 2-3 advocate for surgical treatment. In the remaining patients, a wait-and-see policy might be considered. © 2017 The Author(s).
Original languageEnglish
Pages (from-to)251-259
Number of pages9
JournalHPB
Volume20
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Neuroendocrine Tumors
Primitive Neuroectodermal Tumors
Pancreatic Ducts
Dilatation
Neoplasms
Lymph Nodes
Recurrence
Disease-Free Survival
Multivariate Analysis
Survival Rate
Databases
Morbidity
Mortality

Cite this

Sallinen, VJ., Le Large, TTY., Tieftrunk, E., Galeev, S., Kovalenko, Z., Haugvik, SP., ... group, O. T. B. O. T. P. . R. (2018). Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. HPB, 20(3), 251-259. https://doi.org/10.1016/j.hpb.2017.08.034

Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. / Sallinen, VJ; Le Large, TTY; Tieftrunk, E; Galeev, S; Kovalenko, Z; Haugvik, SP; Antila, A; Franklin, O; Martinez-Moneo, E; Robinson, SM; Panzuto, F; Regenet, N; Muffatti, F; Partelli, S; Wiese, D; Ruszniewski, P; Dousset, B; Edwin, B; Bartsch, DK; Sauvanet, A; Falconi, M; Ceyhan, GO; Gaujoux, S; group, on the behalf of the Pancreas 2000 research.

In: HPB, Vol. 20, No. 3, 2018, p. 251-259.

Research output: Contribution to journalArticle

Sallinen, VJ, Le Large, TTY, Tieftrunk, E, Galeev, S, Kovalenko, Z, Haugvik, SP, Antila, A, Franklin, O, Martinez-Moneo, E, Robinson, SM, Panzuto, F, Regenet, N, Muffatti, F, Partelli, S, Wiese, D, Ruszniewski, P, Dousset, B, Edwin, B, Bartsch, DK, Sauvanet, A, Falconi, M, Ceyhan, GO, Gaujoux, S & group, OTBOTPR 2018, 'Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study', HPB, vol. 20, no. 3, pp. 251-259. https://doi.org/10.1016/j.hpb.2017.08.034
Sallinen, VJ ; Le Large, TTY ; Tieftrunk, E ; Galeev, S ; Kovalenko, Z ; Haugvik, SP ; Antila, A ; Franklin, O ; Martinez-Moneo, E ; Robinson, SM ; Panzuto, F ; Regenet, N ; Muffatti, F ; Partelli, S ; Wiese, D ; Ruszniewski, P ; Dousset, B ; Edwin, B ; Bartsch, DK ; Sauvanet, A ; Falconi, M ; Ceyhan, GO ; Gaujoux, S ; group, on the behalf of the Pancreas 2000 research. / Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. In: HPB. 2018 ; Vol. 20, No. 3. pp. 251-259.
@article{e62d31ff63c04f39a79d8c7c19711b27,
title = "Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study",
abstract = "Background: Malignant potential of small (≤20 mm) nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to predict and management remain controversial. The aim of this study was to assess the prognosis of sporadic nonmetastatic sNF-PNETs. Methods: Patients were identified from databases of 16 centers. Outcomes and risk factors for recurrence were identified by uni- and multivariate analyses. Results: sNF-PNET was resected in 210 patients, and 66{\%} (n = 138) were asymptomatic. Median age was 60 years, median tumor size was 15 mm, parenchyma-sparing surgery was performed in 42{\%}. Postoperative mortality was 0.5{\%} (n = 1), severe morbidity rate was 14.3{\%} (n = 30), and 14 of 132 patients (10.6{\%}) with harvested lymph nodes had metastatic lymph nodes. Tumor size, presence of biliary or pancreatic duct dilatation, and WHO grade 2-3 were independently associated with recurrence. Patients with tumors sized ≤10 mm were disease free at last follow-up. The 1-, 3- and 5-year disease-free survival rates for patients with tumors sized 11-20 mm on preoperative imaging were 95.1{\%}, 91.0{\%}, and 87.3{\%}, respectively. Conclusions: In sNF-PNETs, the presence of biliary or pancreatic duct dilatation or WHO grade 2-3 advocate for surgical treatment. In the remaining patients, a wait-and-see policy might be considered. {\circledC} 2017 The Author(s).",
author = "VJ Sallinen and {Le Large}, TTY and E Tieftrunk and S Galeev and Z Kovalenko and SP Haugvik and A Antila and O Franklin and E Martinez-Moneo and SM Robinson and F Panzuto and N Regenet and F Muffatti and S Partelli and D Wiese and P Ruszniewski and B Dousset and B Edwin and DK Bartsch and A Sauvanet and M Falconi and GO Ceyhan and S Gaujoux and group, {on the behalf of the Pancreas 2000 research}",
year = "2018",
doi = "10.1016/j.hpb.2017.08.034",
language = "English",
volume = "20",
pages = "251--259",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study

AU - Sallinen, VJ

AU - Le Large, TTY

AU - Tieftrunk, E

AU - Galeev, S

AU - Kovalenko, Z

AU - Haugvik, SP

AU - Antila, A

AU - Franklin, O

AU - Martinez-Moneo, E

AU - Robinson, SM

AU - Panzuto, F

AU - Regenet, N

AU - Muffatti, F

AU - Partelli, S

AU - Wiese, D

AU - Ruszniewski, P

AU - Dousset, B

AU - Edwin, B

AU - Bartsch, DK

AU - Sauvanet, A

AU - Falconi, M

AU - Ceyhan, GO

AU - Gaujoux, S

AU - group, on the behalf of the Pancreas 2000 research

PY - 2018

Y1 - 2018

N2 - Background: Malignant potential of small (≤20 mm) nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to predict and management remain controversial. The aim of this study was to assess the prognosis of sporadic nonmetastatic sNF-PNETs. Methods: Patients were identified from databases of 16 centers. Outcomes and risk factors for recurrence were identified by uni- and multivariate analyses. Results: sNF-PNET was resected in 210 patients, and 66% (n = 138) were asymptomatic. Median age was 60 years, median tumor size was 15 mm, parenchyma-sparing surgery was performed in 42%. Postoperative mortality was 0.5% (n = 1), severe morbidity rate was 14.3% (n = 30), and 14 of 132 patients (10.6%) with harvested lymph nodes had metastatic lymph nodes. Tumor size, presence of biliary or pancreatic duct dilatation, and WHO grade 2-3 were independently associated with recurrence. Patients with tumors sized ≤10 mm were disease free at last follow-up. The 1-, 3- and 5-year disease-free survival rates for patients with tumors sized 11-20 mm on preoperative imaging were 95.1%, 91.0%, and 87.3%, respectively. Conclusions: In sNF-PNETs, the presence of biliary or pancreatic duct dilatation or WHO grade 2-3 advocate for surgical treatment. In the remaining patients, a wait-and-see policy might be considered. © 2017 The Author(s).

AB - Background: Malignant potential of small (≤20 mm) nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to predict and management remain controversial. The aim of this study was to assess the prognosis of sporadic nonmetastatic sNF-PNETs. Methods: Patients were identified from databases of 16 centers. Outcomes and risk factors for recurrence were identified by uni- and multivariate analyses. Results: sNF-PNET was resected in 210 patients, and 66% (n = 138) were asymptomatic. Median age was 60 years, median tumor size was 15 mm, parenchyma-sparing surgery was performed in 42%. Postoperative mortality was 0.5% (n = 1), severe morbidity rate was 14.3% (n = 30), and 14 of 132 patients (10.6%) with harvested lymph nodes had metastatic lymph nodes. Tumor size, presence of biliary or pancreatic duct dilatation, and WHO grade 2-3 were independently associated with recurrence. Patients with tumors sized ≤10 mm were disease free at last follow-up. The 1-, 3- and 5-year disease-free survival rates for patients with tumors sized 11-20 mm on preoperative imaging were 95.1%, 91.0%, and 87.3%, respectively. Conclusions: In sNF-PNETs, the presence of biliary or pancreatic duct dilatation or WHO grade 2-3 advocate for surgical treatment. In the remaining patients, a wait-and-see policy might be considered. © 2017 The Author(s).

U2 - 10.1016/j.hpb.2017.08.034

DO - 10.1016/j.hpb.2017.08.034

M3 - Article

VL - 20

SP - 251

EP - 259

JO - HPB

JF - HPB

SN - 1365-182X

IS - 3

ER -